10-Q: Turn Therapeutics Q1 2026 Financials: Increased Burn, New Debt Facility

Turn Therapeutics reports a net loss of $0.97 million for Q1 2026, with cash reserves projected to last into Q1 2027, alongside securing a $25 million debt facility.

Summary

• Turn Therapeutics reported a net loss of $970,972 for the first quarter ended March 31, 2026, compared to a net loss of $328,547 for the same period in 2025.
• Total operating expenses increased significantly to $1,246,143 in Q1 2026 from $384,997 in Q1 2025, driven by higher general and administrative costs.
• Cash and cash equivalents stood at $11,217,671 as of March 31, 2026, an increase from $5,076,144 as of December 31, 2025.
• The company estimates its current cash and cash equivalents will be sufficient to fund operations into the first quarter of 2027.
• A new Loan and Security Agreement was entered into on March 23, 2026, with Avenue Venture Opportunities Fund II, L.P., making available up to $25 million in term loans.
• The company has an accumulated deficit of $23,361,065 as of March 31, 2026.
• The company is advancing its lead investigational therapy, GX-03, for moderate-to-severe atopic dermatitis (AD) and onychomycosis.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, significantly higher operating expenses, and the substantial doubt raised about the company's ability to continue as a going concern, despite securing new financing.

Positives

• Cash and cash equivalents increased to $11.22 million as of March 31, 2026, from $5.08 million as of December 31, 2025.
• Secured a new Loan and Security Agreement providing access to up to $25 million in term loans.
• The company's cash and cash equivalents are projected to be sufficient to fund operations into the first quarter of 2027.
• The lead drug candidate, GX-03, is progressing in clinical trials for atopic dermatitis and onychomycosis.
• The company has FDA-cleared medical devices, with one licensed to Medline Industries, LP.

Negatives

• Net loss for the quarter increased to $970,972 from $328,547 in the prior year period.
• Total operating expenses more than tripled to $1,246,143 in Q1 2026 from $384,997 in Q1 2025.
• The company has a substantial accumulated deficit of $23,361,065 as of March 31, 2026.
• The company's ability to continue as a going concern raises substantial doubt due to expected future cash needs and potential insufficiency of capital resources.
• Significant additional funding of $60 to $65 million is anticipated for Phase 3 trials in 2026 and 2027.

Risks

• The company has a history of net losses and negative cash flows from operations and expects these to continue.
• The company's capital resources may not be sufficient to fund operations through at least the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Failure to obtain additional funding could necessitate significant reductions in the scope of operations, including delaying or terminating product development.
• The development of drug candidates is inherently uncertain, costly, and time-consuming, with no guarantee of regulatory approval or commercial success.
• The company is subject to market risks related to the fair value of derivative liability instruments, including contingent warrant and put option liabilities.
• The company's business is subject to risks associated with clinical trials, regulatory approvals, and market acceptance of its products.

Future Outlook

The company anticipates substantial increases in expenses and operating losses due to ongoing research and development costs for later-stage clinical trials. It expects to require significant additional funding, estimated between $60 to $65 million for Phase 3 trials and $1.5 to $2.5 million for its vaccine program, to be raised through capital markets, equity/debt financing, or strategic collaborations. The company believes its current cash and cash equivalents will be sufficient to fund operations into the first quarter of 2027, but this estimate is based on assumptions that could prove incorrect, potentially depleting resources sooner.

Management Comments

• We believe that our existing cash, cash equivalents and other short term investments will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2027.
• Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that these unaudited condensed consolidated financial statements as of March 31, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.
• We expect to incur additional losses for the foreseeable future, and it is possible we may never achieve or maintain profitability.

Industry Context

StockSavvy.ai notes that Turn Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector. The company's focus on dermatological conditions and a proprietary platform technology positions it within a growing market, but the significant cash burn and reliance on future financing are common challenges for companies at this stage. The secured debt facility provides some near-term financial flexibility, but the ultimate success hinges on clinical trial outcomes and subsequent regulatory approvals.

Comparison to Industry Standards

• Many clinical-stage biotechnology companies experience significant operating losses and negative cash flows from operations, similar to Turn Therapeutics, due to the high costs associated with research and development, particularly clinical trials.
• The need for substantial additional financing is a common characteristic of the biotech industry, with companies often relying on public or private equity offerings, debt financing, and strategic partnerships to fund their operations and development pipelines.
• The projected funding requirement of $60-$65 million for Phase 3 trials is substantial but not unusual for late-stage drug development in the pharmaceutical industry, where costs can escalate significantly.
• The 'going concern' assessment is a frequent disclosure for early-stage biotech firms, highlighting the inherent risks and uncertainties in drug development and the critical importance of securing adequate funding.

Legal Proceedings

• As of March 31, 2026, the company was not a party to any litigation or legal proceedings that, in the opinion of management, are probable to have a material adverse effect on its business.

Related Party Transactions

• In March 2025, the company engaged Davis Polk & Wardwell LLP for legal advisory services. Mr. Arthur Golden, a senior counsel at Davis Polk, joined the Board on September 30, 2025. As of March 31, 2026, outstanding legal costs of approximately $1.2 million were payable to Davis Polk.

Stakeholder Impact

• Shareholders: The increased net loss and continued cash burn may negatively impact share price, while the secured debt facility and potential equity raises could dilute existing ownership.
• Employees: The company's going concern issues and potential need to reduce operations could create job insecurity.
• Creditors: The company has taken on new debt, increasing its leverage.
• Suppliers: Increased operating expenses may lead to higher accounts payable.

Next Steps

• Conduct an interim assessment at approximately 50% trial completion for the GX-03 Phase 2 study in moderate-to-severe AD.
• Advance GX-03 for onychomycosis, following completion of the AD clinical program and related IND activities.
• Continue exploratory work on a thermostable intranasal vaccine platform.
• Access capital markets for additional equity and/or equity-linked securities to fund Phase 3 trials and vaccine program.
• Potentially draw down further tranches of the Avenue Capital loan facility, subject to meeting specific clinical and financing milestones.
• Potentially utilize the Share Purchase Agreement with GEM to raise additional capital.

Key Dates

Recommendation

The company is in a critical clinical development phase with significant financing needs and ongoing losses. While the debt facility and potential equity raises provide runway, the substantial cash burn and 'going concern' doubt warrant caution. The stock is best held pending clearer clinical trial results and a more stable financial footing, rather than a strong buy or sell signal at this juncture.

Keywords

Turn Therapeutics, Form 10-Q, Quarterly Report, Biotechnology, Clinical Stage, Atopic Dermatitis, Onychomycosis, GX-03, Financial Results, Net Loss, Cash Flow, Debt Financing, Equity Financing, SEC Filing